Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Regul Toxicol Pharmacol ; 131: 105159, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35311660

ABSTRACT

Our aim is to develop and apply next generation approaches to skin allergy risk assessment (SARA) that do not require new animal test data and better quantify uncertainties. Significant progress has been made in the development of New Approach Methodologies (NAMs), non-animal test methods, for assessment of skin sensitisation and there is now focus on their application to derive potency information for use in Next Generation Risk Assessment (NGRA). The SARA model utilises a Bayesian statistical approach to infer a human-relevant metric of sensitiser potency and a measure of risk associated with a given consumer exposure based upon any combination of human repeat insult patch test, local lymph node, direct peptide reactivity assay, KeratinoSens™, h-CLAT or U-SENS™ data. Here we have applied the SARA model within our weight of evidence NGRA framework for skin allergy to three case study materials in four consumer products. Highlighting how to structure the risk assessment, apply NAMs to derive a point of departure and conclude on consumer safety risk. NGRA based upon NAMs were, for these exposures, at least as protective as the historical risk assessment approaches. Through such case studies we are building our confidence in using NAMs for skin allergy risk assessment.


Subject(s)
Cosmetics , Dermatitis, Allergic Contact , Hypersensitivity , Animal Testing Alternatives/methods , Animals , Bayes Theorem , Decision Making , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Risk Assessment/methods , Skin
2.
Regul Toxicol Pharmacol ; 127: 105075, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34728330

ABSTRACT

Next generation Risk Assessment (NGRA) is an exposure-led, hypothesis-driven approach which integrates new approach methodologies (NAMs) to assure safety without generating animal data. This hypothetical skin allergy risk assessment of two consumer products - face cream containing 0.1% coumarin and deodorant containing 1% coumarin - demonstrates the application of our skin allergy NGRA framework which incorporates our Skin Allergy Risk Assessment (SARA) Model. SARA uses Bayesian statistics to provide a human relevant point of departure and risk metric for a given chemical exposure based upon input data that can include both NAMs and historical in vivo studies. Regardless of whether NAM or in vivo inputs were used, the model predicted that the face cream and deodorant exposures were low and high risk respectively. Using only NAM data resulted in a minor underestimation of risk relative to in vivo. Coumarin is a predicted pro-hapten and consequently, when applying this mechanistic understanding to the selection of NAMs the discordance in relative risk could be minimized. This case study demonstrates how integrating a computational model and generating bespoke NAM data in a weight of evidence framework can build confidence in safety decision making.


Subject(s)
Bayes Theorem , Cosmetics/toxicity , Coumarins/toxicity , Dermatitis, Contact/pathology , Models, Theoretical , Animal Testing Alternatives , Cell Culture Techniques , Cytochrome P-450 Enzyme System/drug effects , Liver/drug effects , Risk Assessment , Skin Irritancy Tests
3.
J Appl Toxicol ; 39(2): 385-397, 2019 02.
Article in English | MEDLINE | ID: mdl-30345528

ABSTRACT

Skin metabolism is important to consider when assessing local toxicity and/or penetration of chemicals and their metabolites. If human skin supply is limited, pig skin can be used as an alternative. To identify any species differences, we have investigated the metabolism of 10 chemicals in a pig and human skin explant model. Phase I metabolic pathways in skin from both species included those known to occur via cytochrome P450s, esterases, alcohol dehydrogenases and aldehyde dehydrogenases. Common Phase II pathways were glucuronidation and sulfation but other conjugation pathways were also identified. Chemicals not metabolized by pig skin (caffeine, IQ and 4-chloroaniline) were also not metabolized by human skin. Six chemicals metabolized by pig skin were metabolized to a similar extent (percentage parent remaining) by human skin. Human skin metabolites were also detected in pig skin incubations, except for one unidentified minor vanillin metabolite. Three cinnamyl alcohol metabolites were unique to pig skin but represented minor metabolites. There were notable species differences in the relative amounts of common metabolites. The difference in the abundance of the sulfate conjugates of resorcinol and 4-amino-3-nitrophenol was in accordance with the known lack of aryl sulfotransferase activity in pigs. In conclusion, while qualitative comparisons of metabolic profiles were consistent between pig and human skin, there were some quantitative differences in the percentage of metabolites formed. This preliminary assessment suggests that pig skin is metabolically competent and could be a useful tool for evaluating potential first-pass metabolism before testing in human-derived tissues.


Subject(s)
Cosmetics/pharmacokinetics , Skin Absorption/drug effects , Skin/metabolism , Administration, Cutaneous , Animals , Cosmetics/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Glucuronosyltransferase/metabolism , Humans , Metabolic Detoxication, Phase I , Metabolic Detoxication, Phase II , Organ Culture Techniques , Skin/drug effects , Skin/enzymology , Species Specificity , Substrate Specificity , Sulfotransferases/metabolism , Swine , Tissue Distribution
4.
J Appl Toxicol ; 37(7): 806-816, 2017 07.
Article in English | MEDLINE | ID: mdl-28139006

ABSTRACT

Partition (K) and diffusion (D) coefficients are important to measure for the modelling of skin penetration of chemicals through the stratum corneum (SC). We compared the feasibility of three protocols for the testing of 50 chemicals in our main studies, using three cosmetics-relevant model chemicals with a wide range of logP values. Protocol 1: SC concentration-depth profile using tape-stripping (measures KSC/v and DSC /HSC2 , where HSC is the SC thickness); Protocol 2A: incubation of isolated SC with chemical (direct measurement of KSC/v only) and Protocol 2B: diffusion through isolated SC mounted on a Franz cell (measures KSC/v and DSC /HSC2 , and is based on Fick's laws). KSC/v values for caffeine and resorcinol using Protocol 1 and 2B were within 30% of each other, values using Protocol 2A were ~two-fold higher, and all values were within 10-fold of each other. Only indirect determination of KSC/v by Protocol 2B was different from the direct measurement of KSC/v by Protocol 2A and Protocol 1 for 7-EC. The variability of KSC/v for all three chemicals using Protocol 2B was higher compared to Protocol 1 and 2A. DSC /HSC2 values for the three chemicals were of the same order of magnitude using all three protocols. Additionally, using Protocol 1, there was very little difference between parameters measured in pig and human SC. In conclusion, KSC/v, and DSC values were comparable using different methods. Pig skin might be a good surrogate for human skin for the three chemicals tested. Copyright © 2017 The Authors Journal of Applied Toxicology published by John Wiley & Sons Ltd.


Subject(s)
Cosmetics/chemistry , Cosmetics/metabolism , Epidermis/metabolism , Skin Absorption/drug effects , Adult , Animals , Caffeine/metabolism , Coumarins/metabolism , Diffusion/drug effects , Female , Humans , Male , Middle Aged , Models, Animal , Models, Biological , Permeability/drug effects , Resorcinols/metabolism , Swine
5.
Toxicol In Vitro ; 34: 153-160, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27039122

ABSTRACT

The Cosmetics Europe Skin Bioavailability and Metabolism Task Force aims to improve the measurement and prediction of the bioavailability of topically-exposed compounds for risk assessment. Key parameters of the experimental design of the skin penetration studies were compared. Penetration studies with frozen human and pig skin were conducted in two laboratories, according to the SCCS and OECD 428 guidelines. The disposition in skin was measured 24h after finite topical doses of caffeine, resorcinol and 7-ethoxycoumarin. The bioavailability distribution in skin layers of cold and radiolabelled chemicals were comparable. Furthermore, the distribution of each chemical was comparable in human and pig skin. The protocol was reproducible across the two laboratories. There were small differences in the amount of chemical detected in the skin layers, which were attributed to differences in washing procedures and anatomical sites of the skin used. In conclusion, these studies support the use of pig skin as an alternative source of skin should the availability of human skin become a limiting factor. If radiolabelled chemicals are not available, cold chemicals can be used, provided that the influence of chemical stability, reactivity or metabolism on the experimental design and the relevance of the data obtained is considered.


Subject(s)
Caffeine/pharmacokinetics , Cosmetics/pharmacokinetics , Coumarins/pharmacokinetics , In Vitro Techniques/methods , Resorcinols/pharmacokinetics , Skin/metabolism , Administration, Topical , Adult , Animals , Biological Availability , Female , Humans , Male , Middle Aged , Risk Assessment , Skin Absorption , Swine , Young Adult
6.
FEMS Microbiol Lett ; 78(2-3): 287-91, 1992 Dec 01.
Article in English | MEDLINE | ID: mdl-1490612

ABSTRACT

Many bacterial responses to environmental stimuli are mediated by response regulators which coordinately regulate genes involved in particular adaptive responses. Degenerate oligonucleotide primers were used to amplify by the polymerase chain reaction (PCR), fragments from genes encoding eleven novel response regulators. Sequence and phylogenetic analysis revealed that phoB, phoP and creB gene fragments had been amplified from Yersinia enterocolitica and Yersinia pseudotuberculosis, and that a creB sequence had been amplified from Campylobacter jejuni. Four amplified fragments from C. jejuni, Listeria monocytogenes, Mycobacterium tuberculosis and Escherichia coli clearly came from response regulator genes, but were not closely related to any of the known genes. Mutagenesis of the newly identified genes should allow us to determine their function and the genes under their control.


Subject(s)
DNA, Bacterial/genetics , Genes, Bacterial , Polymerase Chain Reaction , Amino Acid Sequence , Bacteria/genetics , Bacteria/pathogenicity , Bacterial Outer Membrane Proteins/genetics , Cloning, Molecular , Genes, Regulator , Molecular Sequence Data , Oligonucleotide Probes , Phylogeny , Sequence Homology, Amino Acid , Species Specificity
7.
J Natl Med Assoc ; 79(11): 1161-3, 1987 Nov.
Article in English | MEDLINE | ID: mdl-3694695

ABSTRACT

Six black hypertensive patients responded favorably to treatment with verapamil hydrochloride (Isoptin). The patients were participants in a larger study.


Subject(s)
Hypertension/drug therapy , Verapamil/therapeutic use , Adult , Aged , Female , Humans , Male , Middle Aged
9.
Food Addit Contam ; 22(8): 716-25, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16147427

ABSTRACT

Bleaching earth (dried, powdered, bentonite-montmorillonite clay) is commonly used as a processing aid in edible oil refinement. Used bleaching earth may be incorporated into animal feed indirectly, for example because it is included into seed meal, or directly (e.g., as a binding agent). Control must be demonstrated to ensure that the levels of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) in feed ingredients do not infringe European Community regulations. The low legislative action level assigned is analytically challenging and may be at or below the limits of quantification achievable by many laboratories. A statistical comparison (following the IUPAC/ISO/AOAC protocol) was made of analyses of PCDDs and PCDFs in selected bleaching earth samples by laboratories from Europe and the USA to assess the comparability of data. Of 19 sets of results submitted by laboratories for replicate samples, 11 demonstrated acceptable agreement.


Subject(s)
Aluminum Silicates/chemistry , Animal Feed , Bentonite/chemistry , Benzofurans/analysis , Dietary Fats, Unsaturated , Polychlorinated Dibenzodioxins/analogs & derivatives , Animals , Clay , Europe , Polychlorinated Dibenzodioxins/analysis , Reproducibility of Results , Soil Pollutants/analysis , United States
10.
J Clin Hypertens ; 1(4): 304-14, 1985 Dec.
Article in English | MEDLINE | ID: mdl-2873208

ABSTRACT

The antihypertensive effect of labetalol was evaluated in 18 adult black patients with mild to moderate essential hypertension previously controlled with a combination of a diuretic and a beta blocker. After a 4-week washout period, standing blood pressure had increased from 138 +/- 2.2/85 +/- 1.5 mmHg, (mean +/- SEM) to 154 +/- 1.9/100 +/- 0.6 mmHg. Labetalol was then titrated to a maximum of 600 mg BID to obtain a standing diastolic blood pressure of less than or equal to 90 mmHg and/or a decrease of greater than or equal to 10 mmHg from baseline (end of washout period). By the end of the labetalol titration period, standing blood pressure had decreased to 140 +/- 2.0/84 +/- 1.5 (p less than 0.01). Following a 2-week maintenance period, standing blood pressure was 136 +/- 1.6/80 +/- 1.5 mmHg (NS vs. titration). Labetalol therapy was well tolerated and reduced diastolic blood pressure to less than or equal to 90 mmHg in 17 of 18 patients, 13 of whom required dosages less than or equal to 300 mg BID. The average reduction in standing heart rate while on labetalol was 4 bpm (p less than 0.01). Side effects were limited to skin rash in one patient and possible mild urinary retention in another. These data indicate that labetalol is an effective antihypertensive for black patients with mild to moderate essential hypertension.


Subject(s)
Black or African American , Hypertension/drug therapy , Labetalol/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Diuretics/therapeutic use , Drug Therapy, Combination , Female , Humans , Labetalol/adverse effects , Male , Middle Aged
11.
Am J Hosp Pharm ; 38(8): 1161-4, 1981 Aug.
Article in English | MEDLINE | ID: mdl-7270561

ABSTRACT

The efficacy and safety of timolol maleate combined with hydrochlorothiazide given once daily compared with hydrochlorothiazide given once daily to patients with hypertension was investigated in a double-blind, randomized study. Patients with uncomplicated, mild to moderate hypertension were admitted to the study. Ten patients received two tablets once daily of timolol maleate 10 mg and hydrochlorothiazide 25 mg (T/H). Nine patients received hydrochlorothiazide 25 mg (HCTZ). Blood pressure and pulse rate measurements and laboratory tests were performed after a six-week placebo baseline period and throughout the 12-week study. Mean supine systolic blood pressure decreased by 21-35 mm Hg for the T/H group and by 10-24 mm Hg for the HCTZ group. Mean supine diastolic blood pressure decreased by 15-22 mm Hg for the T/H group and by 10-13 mm Hg for the HCTZ group. Changes observed in the laboratory variables were not statistically significant between the two treatment groups. One patient in each group had an adverse experience considered unrelated to the drug, and no patient had to discontinue the drug therapy because of an adverse reaction. Although both drug regimens effectively and safely treated uncomplicated mild to moderate hypertension, the timolol maleate and hydrochlorothiazide combination had a greater antihypertensive effect.


Subject(s)
Hydrochlorothiazide/administration & dosage , Hypertension/drug therapy , Propanolamines/administration & dosage , Timolol/administration & dosage , Adult , Drug Administration Schedule , Drug Therapy, Combination , Female , Humans , Hydrochlorothiazide/adverse effects , Hydrochlorothiazide/therapeutic use , Hypertension/physiopathology , Male , Middle Aged , Timolol/adverse effects , Timolol/therapeutic use
12.
Biochem J ; 323 ( Pt 1): 141-6, 1997 Apr 01.
Article in English | MEDLINE | ID: mdl-9173873

ABSTRACT

Nitric oxide synthase (EC 1.14.13.39) is a homodimer. Limited proteolysis has previously shown that it consists of two major domains. The C-terminal or reductase domain binds FMN, FAD and NADPH. The N-terminal or oxygenase domain is known to bind arginine, (6R)-5,6,7,8-tetrahydro-l-biopterin (tetrahydrobiopterin) and haem. The exact residues of the inducible nitric oxide synthase (iNOS) protein involved in binding to these molecules have yet to be identified, although the haem moiety is known to be co-ordinated through a cysteine thiolate ligand. We have expressed two forms of the haem-binding domain of human iNOS (residues 1-504 and 59-504) in Escherichia coli as glutathione S-transferase (GST) fusion proteins. The iNOS 1-504 and 59-504 fusion proteins bound similar amounts of haem, Nomega-nitro-l-arginine (nitroarginine) and tetrahydrobiopterin, showing that the first 58 residues are not required for binding these factors. Using site-directed mutagenesis we have mutated Cys-200, Cys-217, Cys-228, Cys-290, Cys-384 and Cys-457 to alanine residues within the iNOS 59-504 haem-binding domain. Mutation of Cys-200 resulted in a complete loss of haem, nitroarginine and tetrahydrobiopterin binding. Mutants of Cys-217, Cys-228, Cys-290, Cys-384 or Cys-457 showed no effect on the haem content of the fusion protein, no effect on the reduced CO spectral peak (444 nm) and were able to bind nitroarginine and tetrahydrobiopterin at levels equivalent to the wild-type fusion protein. After removal of the GST polypeptide, the wild-type iNOS 59-504 domain was dimeric, whereas the C200A mutant form was monomeric. When the mutated domains were incorporated into a reconstructed full-length iNOS protein expressed in Xenopus oocytes, only the Cys-200 mutant showed a loss of catalytic activity: all the other mutant iNOS proteins showed near wild-type enzymic activity. From this systematic approach we conclude that although Cys-217, Cys-228, Cys-290, Cys-384 and Cys-457 are conserved in all three NOS isoforms they are not essential for cofactor or substrate binding or for enzymic activity of iNOS, and that Cys-200 provides the proximal thiolate ligand for haem binding in human iNOS.


Subject(s)
Antioxidants/metabolism , Biopterins/analogs & derivatives , Cysteine , Heme/metabolism , Nitric Oxide Synthase/chemistry , Nitroarginine/metabolism , Animals , Binding Sites , Biopterins/metabolism , DNA/chemistry , Dimerization , Enzyme Induction , Humans , Nitric Oxide Synthase/metabolism , Protein Conformation , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Xenopus
SELECTION OF CITATIONS
SEARCH DETAIL